References
Abraham E, Wunderink R, Silverman H, et al. Monoclonal antibody to human tumor necrosis factor alpha (TNFa MAb): Efficacy and safety in patients with the sepsis syndrome. JAMA 1995;273:934–941.
Cohen J, Carlet J, for the INTERSEPT Study Group. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 1996;24: 1431–1440.
Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment,MAK195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733–742.
Fisher CJ, Agosti JM, Opal SM, et al. Treatment of patients with septic shock with tumor necrosis factor receptor Fc fusion protein. N Engl J Med 1996;334:1697–1702.
Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A placebo controlled, randomized, double-blind, multi-center clinical trial. JAMA 1997;277:1531–1538.
Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1999;180:2173–2179.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abraham, E. Anti-TNF Strategies. Sepsis 1, 19–20 (1997). https://doi.org/10.1023/A:1009703132434
Issue Date:
DOI: https://doi.org/10.1023/A:1009703132434